Table 2

Current knowledge of medicines R&D by country

GB*
Base=1528
France
Base=1000
Spain
Base=1000
Italy
Base=1000
Poland
Base=1000
Germany
Base=1000
All
Base=6528
Pearson's χ2
p Value
Good knowledge
% (n)
Rank
n
Good knowledge
% (n)
Rank
n
Good knowledge
% (n)
Rank
n
Good knowledge
% (n)
Rank
n
Good knowledge
% (n)
Rank
n
Good knowledge
% (n)
Rank
n
Good knowledge
% (n)
Rank
n
Medicines R&D15% (231)914% (141)912% (123)1024% (242)314% (138)616% (161)716% (1036967.8; df=5; p<0.001
Drug discovery23% (359)323% (227)118% (179)428% (282)219% (189)220% (199)322% (1435)242.7; df=5; p<0.001
Medicines safety28% (429)120% (199)321% (209)130% (296)124% (241)127% (270)125% (1644)145.1; df=5; p<0.001
Patients’ roles and responsibilities20% (303)718% (177)819% (193)320% (201)815% (151)518% (179)518% (1204)712.4; df=5; p<0.05
Personalised medicine22% (335)519% (187)517% (169)624% (242)313% (131)916% (155)719% (1219)559.6; df=5; p<0.001
Predictive medicine23% (356)319% (188)520% (196)221% (211)714% (141)619% (191)420% (1283)434.4; df=5; p<0.001
Design and objectives of clinical trials28% (429)122% (224)216% (156)724% (241)317% (172)321% (214)222% (1436)272.7; df=5; p<0.001
Health technology assessment20% (303)720% (196)318% (175)424% (240)317% (169)315% (148)919% (1231)533.1; df=5; p<0.001
Pharmacoeconomics17% (264)1013% (134)1015% (145)819% (186)911% (108)1013% (125)1015% (962)1036.8; df=5′ p<0.001
Regulation22% (343)519% (191)514% (141)918% (183)1014% (139)618% (183)518% (1180)742.9; df=5; p<0.001
  • *Participants aged 65 years and older removed from Great Britain (GB) sample to ensure that all countries were comparable by age.